Biography
Dr Yong Du is a Consultant Physician in Nuclear Medicine at Icon Cancer Centre London. He completed Nuclear Medicine specialist training at the Institute of Nuclear Medicine in University College London Hospital (UCLH) and obtained his PhD degree in radioimmunotherapy for lymphoma.
Dr Yong Du has extensive expertise in PET/CT imaging and radionuclide targeted therapy. He leads the radionuclide therapy services at the Royal Marsden Hospital, the biggest cancer centre in the UK since January 2011, he’s also in the NHS England advisory group for radionuclide targeted therapy, and British Nuclear Medicine Society and Royal College of Physicians representative to NICE on Clinical Nuclear Medicine.
He’s published first-authored research articles in high impact oncology journals including Journal of Clinical Oncology, Blood, Cancer Research. He was the first recipient of the UK HEFCE Clinical Senior Lectureship Award in the Nuclear Medicine specialty.
Dr Yong Du pioneered Lu-177-PSMA treatment for prostate cancer patients in the United Kingdom and was awarded the first clinical ARSAC licence to treat in February 2018. Using this novel technology, he has treated over 300 patients, he has also treated a large number of patients using other radionuclides including 131I for thyrotoxicosis and thyroid cancer, Zevalin for lymphoma, MIBG for neuroblastoma, Radium-223 (Xofigo) for prostate cancer, and PRRT for neuroendocrine tumour.
Other posts held
The Royal Marsden Hospital
GMC: 6127896